Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A

1(50.0%)

Phase 2

1(50.0%)

2Total

N/A(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT06314841Terminated

Polytrauma and Resuscitation Impact on Innate Immunity

Role: collaborator

NCT04474106Not ApplicableRecruiting

NEUROwave - Extracorporeal Shock Wave Therapy (ESWT) in Acute Traumatic Complete (AIS A) and Incomplete (AIS B-D) Cross-sectional Lesions on Motor and Sensory Function Within Six Months After Injury

Role: lead

NCT04354779Completed

Antibody Seroprevalence and Rate of Asymptomatic Infections With SARS-CoV-2 in Austrian Hospital Personnel.

Role: lead

NCT02760589Completed

Magnetic Resonance Imaging and Functional Performance Outcome After ACL Repair With Internal Brace Technique

Role: lead

NCT00545896Phase 2Completed

Extracorporeal Shockwave Treatment for Chronic Soft Tissue Wounds

Role: lead

All 5 trials loaded